CA125、CA19-9联合检测在卵巢上皮癌与子宫内膜异位症中的价值

The Value of Combined Detection of CA19-9 and CA125 in Ovarian Epithelial Carcinoma and Endometriosis

肿瘤标记物是存在于恶性肿瘤组织中的特异性表达的糖蛋白类抗原物质,其对于肿瘤的早期发现和检测乃至靶向治疗具有重要的意义。目前临床采用CA125作为卵巢恶性肿瘤的标记物,并且其诊断价值也得到了一定的认可。但有临床研究发现,CA125对于上皮性卵巢肿瘤的早期诊断的确诊率比较低,同时还发现,其主要对于某些非粘液性囊腺癌特别是浆液性囊腺癌较为敏感。由于一种肿瘤可能同时出现多种肿瘤标记物,以及不同的肿瘤疾病可能出现同一种肿瘤标记物,因此,几种肿瘤标记物对某种疾病进行联合检测能够有效提高肿瘤的确诊率。据相关的文献资料报道,CA125、CA19-9联合检测能够提高卵巢恶性肿瘤的确诊率。

To study is found in malignant tumor tissue specific expression of the glycoprotein antigens substances, its to early detection and detection and target therapy for tumor has the vital significance. The current clinical use as ovarian malignant tumor markers CA125, and its diagnostic value also got certain recognition. But there are clinical study found that CA125 for epithelial sex in the early diagnosis of ovarian tumors confirmed rate is lower, at the same time, also found that the group for some non mucous cystadenocarcinoma especially sensitive serous cystadenocarcinoma. Due to a tumor may also appear a variety of tumor markers, as well as the different tumor disease may appear the same kind of tumor markers,therefore, the choice of a disease for joint detection of tumor markers can effectively improve the positive rate of tumor. According to relevant literature reports, CA125, CA19-9 joint detection can improve the positive rate of ovarian malignant tumors.